---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-23-000079"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:47:58.229022+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Maravai Q2 revenue $68.9M, down 72%; net loss $11.9M; CEO transition to Trey Martin

## Summary
- Revenue $68.9M, down 71.6% YoY; net loss $(11.9)M vs net income $156.7M prior year.
- Nucleic Acid Production revenue $53.3M (-76.4%), including $11.6M CleanCap; Biologics Safety Testing $15.6M (-10.5%).
- Appointed Trey Martin as CEO effective July 27, 2023; Carl Hull remains Executive Chair.
- Took occupancy of new 32,000-sq-ft cGMP mRNA facility in San Diego; expanded enzyme R&D in Florida.
- Updated 2023 financial guidance conservatively; no specific numbers provided in filing.

## SEC filing metadata
- accession: 0001823239-23-000079
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/mrvi-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-23-000079
- JSON: https://secwatch.observer/filing/0001823239-23-000079.json
- Plain text: https://secwatch.observer/filing/0001823239-23-000079.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. updated its the full year 2023 guidance (lowered).
  - Period: the full year 2023
  - Guidance: lowered
  - Result: guidance update
  source text: we are taking a more conservative view of our financial guidance for the full year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported the six months ended June 30, 2023 results: revenue $147.9 million, net income Net loss ... $(13.3) million. Guidance reaffirmed.
  - Period: the six months ended June 30, 2023
  - Revenue: $147.9 million
  - Net income: Net loss ... $(13.3) million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Revenue for the six months ended June 30, 2023 was $147.9 million, representing a 70% decrease over the same period in the prior year
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported the second quarter ended June 30, 2023 results: revenue $68.9 million, net income Net loss of $(11.9) million. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $68.9 million
  - Net income: Net loss of $(11.9) million
  - Guidance: reaffirmed
  - Result: reported results
  source text: innovators, today reported financial results for the second quarter ended June 30, 2023, together with other business updates. Recent highlights include: • Quarterly revenue of $68.9 million, Net loss of $(11.9) million, and Adjusted EBITDA margin of 13.2%; • Completed planned leadership transition with the appointment of Trey Martin as CEO effective July 27, 2023,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000079/0001823239-23-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.